Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...

A novel transcatheter-implanted system that shunts blood flow from the left to right atrium through the coronary sinus has ...

Payouts to shareholders of large publicly traded health companies more than tripled over the past two decades, new research ...

Novo Nordisk announced plans for a longer phase III trial testing its investigational obesity drug CagriSema, with regulatory ...

Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...

Shares of Amgen Inc. AMGN shed 1.42% to $293.54 Friday, on what proved to be an all-around dismal trading session for the ...

At recent prices, you can buy shares of Merck (NYSE: MRK) that offer a yield above 3%, and shares of Pfizer (NYSE: PFE) offer ...

While Ideaya is letting Amgen go, it is retaining an interest in MAT2A-PRMT5 combinations. Ideaya has a PRMT5 inhibitor, ...

Gladstone Institutional Advisory LLC trimmed its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 18.9% in the fourth ...

Murdo Gordon, Executive Vice President of Global Commercial Operations at Amgen Inc . (NASDAQ:AMGN), recently sold a significant portion of the company's stock. According to a filing with the ...

Amgen, Inc. ( NASDAQ: AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call February 12, 2025 11:20 AM ET Narimon Honarpour - Senior Vice President, Global Development Justin Claeys - ...

Amgen (NASDAQ:AMGN – Get Free Report) had its target price increased by Piper Sandler from $310.00 to $329.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently ...